KA Kineta Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KA

Price (delayed)

$0.5834

Market cap

$6.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.28

Enterprise value

$1.85M

Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced ...

Highlights
The company's EPS has surged by 90% YoY and by 88% QoQ
The net income has soared by 78% YoY and by 76% from the previous quarter
KA's gross profit has soared by 179% year-on-year but it is down by 8% since the previous quarter
The revenue has soared by 179% YoY but it has contracted by 8% from the previous quarter
Kineta's quick ratio has decreased by 28% YoY and by 18% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.proteostasis.com
Peers: OMER OMGA

Key stats

What are the main financial stats of KA
Market
Shares outstanding
10.96M
Market cap
$6.4M
Enterprise value
$1.85M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.1
Price to sales (P/S)
1.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.34
Earnings
Revenue
$5.44M
EBIT
-$13.76M
EBITDA
-$13.01M
Free cash flow
-$15.88M
Per share
EPS
-$1.28
Free cash flow per share
-$1.44
Book value per share
$0.28
Revenue per share
$0.49
TBVPS
$0.93
Balance sheet
Total assets
$10.28M
Total liabilities
$7.22M
Debt
$1.32M
Equity
$2.89M
Working capital
-$1.1M
Liquidity
Debt to equity
0.46
Current ratio
0.85
Quick ratio
0.83
Net debt/EBITDA
0.35
Margins
EBITDA margin
-239.1%
Gross margin
100%
Net margin
-259.1%
Operating margin
-288.9%
Efficiency
Return on assets
-109.4%
Return on equity
-436%
Return on invested capital
N/A
Return on capital employed
-428.9%
Return on sales
-252.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KA stock price

How has the Kineta stock price performed over time
Intraday
4.18%
1 week
-2.77%
1 month
9.7%
1 year
-86.59%
YTD
-83.57%
QTD
12.63%

Financial performance

How have Kineta's revenue and profit performed over time
Revenue
$5.44M
Gross profit
$5.44M
Operating income
-$15.72M
Net income
-$14.1M
Gross margin
100%
Net margin
-259.1%
KA's gross profit has soared by 179% year-on-year but it is down by 8% since the previous quarter
The revenue has soared by 179% YoY but it has contracted by 8% from the previous quarter
The net margin has soared by 92% YoY and by 74% from the previous quarter
Kineta's operating margin has soared by 86% YoY and by 55% from the previous quarter

Growth

What is Kineta's growth rate over time

Valuation

What is Kineta stock price valuation
P/E
N/A
P/B
2.1
P/S
1.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.34
The company's EPS has surged by 90% YoY and by 88% QoQ
The stock's price to book (P/B) is 41% less than its 5-year quarterly average of 3.4
KA's equity is down by 35% YoY but it is up by 6% from the previous quarter
The revenue has soared by 179% YoY but it has contracted by 8% from the previous quarter
The price to sales (P/S) is 86% lower than the last 4 quarters average of 8.4

Efficiency

How efficient is Kineta business performance
The company's return on sales has surged by 92% YoY and by 73% QoQ
The return on assets has surged by 73% since the previous quarter and by 68% year-on-year
The ROE has soared by 73% since the previous quarter and by 49% year-on-year

Dividends

What is KA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KA.

Financial health

How did Kineta financials performed over time
KA's total assets is 42% greater than its total liabilities
Kineta's total liabilities has decreased by 44% YoY and by 8% from the previous quarter
KA's total assets is down by 41% year-on-year and by 4% since the previous quarter
The debt is 54% less than the equity
The debt has contracted by 42% YoY and by 19% from the previous quarter
KA's equity is down by 35% YoY but it is up by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.